Search
ProKidney Corp
PROKAdd to Watchlist
1.045USD
-0.105-9.13%
Close 11-13 16:00（ET）
315.92MMarket Cap
LossP/E TTM
ProKidney Corp (PROK) Stock Price Target & Forecast
Analyst Rating
Based on 8 analysts giving stock ratings to ProKidney Corp in the past month.
Buy
3 Strong Buy
1 Buy
3 Hold
1 Sell
0 Strong Sell
Target Price
6.500USD+401.93%
PROK Analyst Recommendation Trends
In the current month, PROK has received 1 Buy Ratings, 3 Hold Ratings, and 1 Sell Ratings. PROK average Analyst price target in the last month is 6.500.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
3
3
3
3
3
3
3
3
1
1
2
2
2
2
2
2
3
3
3
3
3
3
3
3
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
8
8
9
9
9
9
9
9
PROK Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ascendis Pharma A/S
ASND
9
13
1
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
6
0
0
22
Financial Forecasting
Based on analysts' estimates, PROK EPS is projected to reach -0.141 in FY2026Q4, following reported EPS of -0.171 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.14
-0.14
-0.14
-0.14
-0.14
Actual
-0.14
-0.15
-0.17
--
--
Surprise
-2.30%
-8.30%
-20.98%
--
--
FAQs
What is ProKidney Corp's expected revenue for the next quarter?
ProKidney Corp's expected revenue is 128.60K.
What is ProKidney Corp's price target?
Analysts forecast that ProKidney Corp's price target is USD 6.50, with the highest forecast at USD 12.00 and the lowest forecast at USD 1.00.
How have ProKidney CorpPROK's recent earnings per share performed?
The market expectation was USD -0.17, while ProKidney CorpPROK's earnings per share (EPS) for the previous quarter was USD -0.15. EPS for the next quarter is expected at USD -0.14.
What is the analyst rating for ProKidney Corp?
Based on the ratings of ProKidney Corp's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.